¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"bubble structure"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • electron structure
    ÀüÀÚ±¸Á¶
  • immunoglobulin structure
    ¸é¿ª±Û·ÎºÒ¸°±¸Á¶
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • structure
    ±¸Á¶
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary structure
    ÀÏÂ÷±¸Á¶(¡­Ï°ðã).
  • pseudoknot RNA structure
    ¸ÅµìÇü RNA ±¸Á¶
  • quasicrystalline structure
    ÁذáÁ¤±¸Á¶(ñÞÌ¿ïÜϰðã).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • alveolar structure
    ÆóÆ÷±¸Á¶(¡­Ï°ðã)
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
  • antigenic structure
    Ç׿ø±¸Á¶(¡­Ï°ðã).
  • atomic structure
    ¿øÀÚ±¸Á¶(¡­Ï°ðã).
  • atomic structure
    ¿øÀÚ±¸Á¶
  • bone structure
    »À±¸Á¶, °ñ±¸Á¶(Íéϰðã).
  • chain structure
    ¿¬¼â±¸Á¶(ææáðϰðã).
  • chemical structure
    È­ÇÐÀû ±¸Á¶
  • chemical structure
    È­Çб¸Á¶(¡­Ï°ðã).
  • cognitive structure
    ÀÎÁö±¸Á¶(ìãò±Ï°ðã)
  • core structure
    Á᫐ ±¸Á¶¹°
  • decidua structure
    Å»¶ô¸·±¸Á¶
  • diamond structure
    ´ÙÀ̾Ƹóµå±¸Á¶(¡­Ï°ðã).
  • discoid structure
    ¿ø¹Ý±¸Á¶
  • domain structure
    ¿µ¿ª±¸Á¶
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • noncovalent structure
    ºñ°ø À¯±¸Á¶(ÞªÍëêóϰðã)
  • primary structure
    ÀÏÂ÷±¸Á¶(ìéó­Ï°ðã)
  • protein structure
    ´Ü¹éÁú ±¸Á¶(Ó±ÛÜòõϰðã)
  • quaternary structure
    »çÂ÷(ÞÌó­) ±¸Á¶(ϰðã).
  • quinary structure
    ¿ÀÂ÷(çéó­) ±¸Á¶(ϰðã).
  • secondary structure
    ÀÌÂ÷ ±¸Á¶(ì£ó­Ï°ðã)
  • sigma structure
    ½Ã±×¸¶±¸Á¶(ϰðã)
  • solenoid structure
    ¼Ö·¹³ëÀÌµå ±¸Á¶(ϰðã)
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
  • tertiary structure
    »ïÂ÷±¸Á¶ (ß²ó­Ï°ðã)
  • theta structure
    ½ÃŸ ±¸Á¶(ϰðã)
  • x-ray structure
    X¼±(àÊ) ±¸Á¶(ϰðã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
hfs hyperfine structure
LFS lateral facet syndrome; Li-Fraumeni syndrome; limbic forebrain structure; liver function series
MTS Medicare transaction system; magnetization transfer contrast; methotrexate; multicellular tumor sphe...
QSAR quantitative structure-activity relationship
ROPS rollover protective structure
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
QSRR Quantitative structure retention relationships
SCSA Sperm Chromatin Structure Assay
SAR Structure activity relationship
SCID Structure Clinical Interview for DSM-III-R
SFM Structure-from-motion
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • encapsulated structure
    Çdz¶ ±¸Á¶
  • extracranial structure
    µÎ°³¿Ü ±¸Á¶¹°
  • locomotor structure
    ¿îµ¿ ±¸Á¶¹°
  • monoclinic structure
    ´Ü»ç ±¸Á¶
  • mosaic structure
    ¸ðÀÚÀÌÅ© ±¸Á¶
  • neurologic structure
    ½Å°æ ±¸Á¶
  • organomineral structure
    À¯±â ¹«±âÁú ±¸Á¶
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • peripheral structure
    ¸»ÃÊ Á¶Á÷
  • quasicrystalline structure
    ÁذáÁ¤ ±¸Á¶
  • retromandibular structure
    ¾ÇÈÄ ±¸Á¶, ÇÏ¾Ç ÈĹæºÎ ±¸Á¶¹°
  • secondary structure
    ÀÌÂ÷ ±¸Á¶
  • somatic structure
    ü¼º ±¸Á¶
  • structure
    ±¸Á¶
  • submandibular structure
    ¾ÇÇÏ ±¸Á¶
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
protein structure, secondary The stage in the development of protein structure in which regular hydrogen-bond interactions within contiguous stretches of polypeptide chain give rise to alpha helices and beta sheets. This is the first folding level of protein building.
(12 Dec 1998)
protein structure, tertiary The stage in the structural development of a protein in which combinations of alpha helices and beta sheets pack together to form compactly folded globular units named domains. Small proteins consist of only one domain but larger proteins contain a number of domains which are usually connected by open lengths of polypeptide chain. This stage is a combination of the second and third folding levels of protein building.
(12 Dec 1998)
secondary structure <molecular biology> Structures produced in polypeptide chains involving interactions between amino acids within the chain. Especially _ helical and _ pleated sheet structures. Also applies to the complex folding of nucleic acids as, for example: the clover leaf structure of tRNA.
(18 Nov 1997)
Holliday structure <molecular biology> A structure which occurs during homologous recombination between homologous chromosomes. While the two chromosomes are side by side, one strand of DNA on each chromosome is broken and then attached to the broken strand of DNA on the other chromosome. The crossover point, which is called the Holliday junction, is able to slide up and down between the two chromosomes, so that a little or a lot of DNA can ultimately be switched between them.
(09 Oct 1997)
soil structure The combination or arrangement of primary soil particles into secondary particles, units or peds.
(09 Oct 1997)
stem and loop structure <molecular biology> The structure of tRNAs is so termed because it has four base paired stems and three loops (not base paired), one of which contains the anticodon.
(18 Nov 1997)
structure <microscopy> The mode of construction of an animate or inanimate body or system from units such as atoms, ions, molecules, cells, crystals in a fluid, plastic, or solid state. Cf. Morphology.
(05 Aug 1998)
structure activity analysis Study in which systematic variation in the structure of a compound is correlated with its activity, in an attempt to determine the characteristics of the (receptor) site at which it acts.
(18 Nov 1997)
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
structure-functionalism The scientific tradition that stresses the relationship between aphysical structure and its function, for example: the related disciplinesof anatomy and physiology.
(09 Oct 1997)
structure proteins Proteins whose role is for structure and support in tissue and within the cell; e.g., the collagens.
(05 Mar 2000)
quarternary structure The three-dimensional structure of a complex protein, this especially refers to the way the subunits fit together.
(09 Oct 1997)
quaternary structure The three-dimensional structure of a complex protein, this especially refers to the way the polypeptide subunits fit together.
(09 Oct 1997)
tertiary structure <biochemistry, chemistry> The third level of structural organisation in a macromolecule.
The primary structure of a protein (for example) is the amino acid sequence, the secondary structure is the folding of the peptide chain (alpha helical or beta pleated), the tertiary structure is the way in which the helices or sheets are folded or arranged to give the three dimensional structure of the protein. Quaternary structure refers to the arrangement of protomers in a multimeric protein.
(13 Jan 1998)
ecosystem structure The physical and spatial aspects of an ecosystem that are contributed by the biotic composition. Biotic composition is generally determined by the collective physiognomy of the dominant plants, including life forms, vertical stratification, and size.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • primary structure
    ÃÊ¿øÀû ±¸Á¶¹°(ÃÖ¼ÒÇÑÀÇ Á¶Çü ¼ö´ÜÀ¸·Î Á¦À۵Ǵ ÀüÀ§ Á¶°¢)
  • structure
    ¹°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á